LX7101 is primarily used in the field of ophthalmology as a potential therapeutic agent for treating ocular conditions. It is being investigated for its efficacy in managing diseases such as glaucoma, where it helps in reducing intraocular pressure by targeting specific pathways involved in fluid regulation within the eye. Additionally, LX7101 is explored for its anti-fibrotic properties, which could be beneficial in preventing or treating scarring and fibrosis that may occur after ocular surgeries or injuries. Its mechanism of action involves modulating cellular processes that contribute to inflammation and tissue remodeling, making it a promising candidate for improving patient outcomes in various eye-related disorders. Research is ongoing to further validate its safety and effectiveness in clinical settings.